Delcath Systems
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
66 Queensbury Ave, Queensbury, New York,...Phone Number
(917) 902-6455Website
www.delcath.comRevenue
$95.4 MillionStock Symbol
DCTHIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, NY.Explore more
Delcath Systems Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Delcath Systems your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Delcath Systems
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Delcath Systems is spiking on competitors!
Delcath Systems, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Delcath Systems had a recent Job posting/layoffs
Check if Delcath Systems has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Delcath Systems has new funding data
Earning: See what the market has to say on Delcath Systems recently announced quarterly report
Product Launch: Get notified when Delcath Systems launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Delcath Systems
Compare insights from companies similar to Delcath Systems, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Delcath Systems is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Delcath Systems is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Delcath Systems.
Delcath Systems financials insights
Gather financial insights about Delcath Systems, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2000
Stock Offering
$7.2M
2023
Other Financing Round
$85M
2024
Series E
$16.3M
Delcath Systems Tech Stack
A closer look at the technologies used by Delcath Systems
See more technologies
Most Recent Scoops
Earnings
Delcath Systems has reported selling, general and administrative expense of $13.4 million, compared to $11.4 million in Q2 2025, reflecting investment in continued commercial expansion and increased marketing activities.
Earnings, Spending/Investment, Marketing Campaign, Finance
Project
Delcath Systems has reported that independent investigators presented a retrospective analysis at ESMO Breast Cancer in May 2026 of 15 heavily pretreated patients with liver-dominant metastatic breast cancer treated with percutaneous hepatic perfusion, with nine of the 15 patients demonstrating a hepatic partial response, supporting further evaluation of this approach.
Medical Research
Project
Delcath Systems has reported that its sponsored phase II trial in metastatic colorectal cancer now has 13 centers actively screening, with recruitment improving following the addition of sites and the application of specialized training and streamlined onboarding, targeting an estimated addressable population of approximately 6,000 to 10,000 U.S. patients annually with liver-dominant disease in the third-line setting.
Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Delcath Systems has raised its full-year revenue guidance to a range of $104 million to $108 million, reflecting at least 28% growth in HEPZATO KIT volume over 2025, driven primarily by first-half performance and the pace of new patient starts.
Earnings, Forecasting, Finance
Project
Medical Research, Clinical Operations
Delcath Systems News & Media
Delcath Systems Q1 Earnings Call Highlights
Delcath Systems (NASDAQ:DCTH) reported first-quarter 2026 revenue growth and reiterated its full-year outlook, while updating expectations for U.S. treatment-center activations and outlining progress across ongoing clinical programs. Executives pointed to record new patient starts and the impact ofDelcath Systems publishes results from subgroup analyses of FOCUS study
Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in the Journal of Cancer Research and Clinical Oncology. The analysis assessed efficacy and safety in subgroups of patients treated with Delcath’s Hepzato Kit, a drug/device combination for liver-directed treatment of mUM patients. The Hepzato Kit is currently the only liver-directed treatment to be approved by the FDA for patients with unresectable mUM. ThHere’s What Hit Delcath Systems (DCTH) in Q3
Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. The strategy reported solid absolute returns in the quarter but lagged the benchmark as it did not keep pace with the strong rally. The strategy continues to focus on quality companies […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Delcath Systems
Sign Up For FreeTo access detailed company insights
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic C... Read More
